Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Vertex Pharmaceuticals' business will suffer if other drugmakers launch competing cystic fibrosis drugs. Despite this threat, Vertex Pharmaceuticals' core franchise looks safe for the foreseeable ...
While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on ...
As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. After ...
Zacks Investment Research on MSN
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug ...
Vertex Pharmaceuticals halted a cystic fibrosis program in the works with Moderna over lung inflammation concerns. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results